AIM URINAL RING ENCOUNTER

المعلومات الرئيسية

  • اسم تجاري:
  • AIM URINAL RING ENCOUNTER
  • يسخدم من اجل:
  • البشر
  • نوع الدواء:
  • الجهاز الطبي

المستندات

  • لعامة الناس:
  • النشرة المعلومات عن هذا المنتج غير متوفر حاليا، يمكنك إرسال طلب لخدمة العملاء لدينا، ونحن سوف يخطر لك في أقرب وقت ونحن قادرون على الحصول عليه.


    طلب نشرة المعلومات لعامة الناس.

الأقلمة

  • متاح في:
  • AIM URINAL RING ENCOUNTER
    كازاخستان
  • اللغة:
  • العربية

معلومات أخرى

الحالة

  • المصدر:
  • Ecolab
  • تخويل:
  • 987586
  • اخر تحديث:
  • 12-03-2018

ملخص خصائص المنتج

AIM URINAL RING ENCOUNTER

987586

1 / 7

AIM URINAL RING ENCOUNTER

00971 4 8014444

00971 48146800 00971 4 8014000

0020 2 25 37 1195

00212 22 58 25 30 - 35

00971 4 8014444 :

00971 48146800 00971 4 8014000

0020 2 25 37 1195 :

00212 22 58 25 30 - 35 :

29.06.2017

GHS

AIM URINAL RING ENCOUNTER

987586

2 / 7

:

:

(%)

497-19-8

10 - 30

amides, coco, n-(hydroxyethyl)

68140-00-1

10 - 30

Polyethylene Glycol

25322-68-3

10 - 30

25155-30-0

10 - 30

Fatty acids, coco, sodium salts

61789-31-9

10 - 30

sodium tetraborate - pentahydrate

12179-04-3

5 - 10

AIM URINAL RING ENCOUNTER

987586

3 / 7

0 °C

45 °C

sodium tetraborate -

pentahydrate

12179-04-3

TWA OEL-RL

1 mg/m3

sodium tetraborate -

pentahydrate

12179-04-3

2 ppm

6 mg/m3

ARE OEL

AIM URINAL RING ENCOUNTER

987586

4 / 7

AIM URINAL RING ENCOUNTER

987586

5 / 7

4,467 mg/kg :

4 h :

33.33 mg/l :

Polyethylene Glycol

20,000 mg/kg :

sodium tetraborate - pentahydrate

2,000 mg/kg :

AIM URINAL RING ENCOUNTER

987586

6 / 7

96 h :

LC50

300 mg/l :

Polyethylene Glycol

96 h :

LC50

> 1,000 mg/l :

96 h :

LC50

3.2 mg/l :

sodium tetraborate - pentahydrate

96 h :

LC50

> 100 mg/l :

48 h :

EC50

213.5 mg/l :

amides, coco, n-(hydroxyethyl)

72 h :

EC50

1.07 mg/l :

AIM URINAL RING ENCOUNTER

987586

7 / 7

(ADR/ADN/RID)

)

(

)

IMDG/

(

29.06.2017

Regulatory Affairs

  • النشرة المعلومات عن هذا المنتج غير متوفر حاليا، يمكنك إرسال طلب لخدمة العملاء لدينا، ونحن سوف يخطر لك في أقرب وقت ونحن قادرون على الحصول عليه.

    طلب نشرة المعلومات لعامة الناس.



  • وثائق في اللغات الأخرى المتاحة هنا

1-6-2018

SunMed Holdings, LLC Issues a Nationwide Recall of STAT-Check and Medline Manual Resuscitator Bags

SunMed Holdings, LLC Issues a Nationwide Recall of STAT-Check and Medline Manual Resuscitator Bags

On May 29, 2018, SunMed Holdings, LLC initiated a nationwide recall of 18,808 units of STAT-Check and Medline resuscitator bags which were distributed between February 1, 2018 to May 13, 2018. The patient port retaining ring of the affected bags may not fully seat which may allow the patient port to detach during use. If this takes place, the resuscitator bags may not deliver air to the patient and result in a delay in treatment and life-threatening health consequences. There have been no reported injuri...

FDA - U.S. Food and Drug Administration

1-6-2018

STAT-Check and Medline Manual Resuscitator Bags by SunMed Holdings: Recall - Patient Port May Detach During Use

STAT-Check and Medline Manual Resuscitator Bags by SunMed Holdings: Recall - Patient Port May Detach During Use

The patient port retaining ring of the affected bags may not fully seat which may allow the patient port to detach during use.

FDA - U.S. Food and Drug Administration

8-6-2015

Many addictive drugs lacked statutory packaging seal

Many addictive drugs lacked statutory packaging seal

The Danish Health and Medicines Authority’s laboratory has made a thorough investigation and found that 70 of 229 addictive drugs in the Danish market lacked the statutory packaging seal on the outer packaging. The seal makes it easy to determine whether the package has been broken before it reaches the end user. The aim is to prevent abuse.

Danish Medicines Agency

5-7-2018

Scientific guideline:  Draft guideline on the use of adjuvanted veterinary vaccines, draft: consultation open

Scientific guideline: Draft guideline on the use of adjuvanted veterinary vaccines, draft: consultation open

The main aim of the guideline is to outline the information which should be included for the adjuvant in the marketing authorisation application (MAA) of an immunological veterinary medicinal product (IVMP). This guideline replaces the ‘Note for Guidance on the use of adjuvanted veterinary vaccines’. The guideline discusses the important aspects to consider for the adjuvant in an IVMP and provides guidance on the information on the adjuvant which should be included in Parts 2, 3 and 4 of the MAA. The d...

Europe - EMA - European Medicines Agency